Scientists Say They ’ve Reached Turning Point in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine.
After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years.
These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer.
More from TIME
[video id=W5jcvwLu autostart="viewable"]
“We’re getting something to work. Now we need to get...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news
Scientists Say They ’ve Reached ‘Turning Point’ in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine.
After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years.
These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer.
“We’re getting something to work. Now we need to get it to work better,” said Dr. James Gulley, who help...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 -- (Healthcare Sales & Marketing Network) -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leadin... Biopharmaceuticals, Oncology Sirnaomics, RNAi therapeutics, squamous cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 19, 2023 Category: Pharmaceuticals Source Type: news
SBI: The presence of LCIS indicates increased breast cancer risk
Lobular carcinoma in situ (LCIS) is both a cancer precursor indicator and ...Read more on AuntMinnie.comRelated Reading:
Is screening breast MRI needed for women with high-risk lesions?
How should architectural distortions on DBT be managed?
FES-PET/CT can help detect breast cancer
Chest wall ultrasound good alternative after mastectomy
AI, breast density assessment spot more interval cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 9, 2023 Category: Radiology Source Type: news
SBI: DCIS progression appears as new masses on surveillance imaging
Surveillance imaging of women with ductal carcinoma in situ (DCIS) that ha...Read more on AuntMinnie.comRelated Reading:
Half of DCIS-treated women don't get ongoing imaging surveillance
Is palpable DCIS more aggressive than screen-detected?
Ultrafast MRI shows promise in predicting DCIS upstaging
Ultrasound guidance effective in DCIS surgery
DWI-MRI predicts whether women's DCIS will upstage after surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 8, 2023 Category: Radiology Source Type: news
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
DCISionRT(R) by PreludeDx(TM) Receives Advanced Diagnostic Laboratory Test (ADLT) Status Approval from the Centers for Medicare and Medicaid Services
LAGUNA HILLS, Calif., March 28, 2023 -- (Healthcare Sales & Marketing Network) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the Centers for Medicare & Med... Diagnostics, Oncology PreludeDx, DCISionRT test, ductal carcinoma in situ (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2023 Category: Pharmaceuticals Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Half of DCIS-treated women don't get ongoing imaging surveillance
More than half of women treated for ductal carcinoma in situ (DCIS) do not consistentl...Read more on AuntMinnie.comRelated Reading:
Is palpable DCIS more aggressive than screen-detected?
Ultrafast MRI shows promise in predicting DCIS upstaging
Screening breast imaging findings differ between Black and white women
Ultrasound guidance effective in DCIS surgery
DWI-MRI predicts whether women's DCIS will upstage after surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 11, 2023 Category: Radiology Source Type: news
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Source: World Pharma News)
Source: World Pharma News - December 16, 2022 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Is palpable DCIS more aggressive than screen-detected?
Palpable ductal carcinoma in situ (DCIS) does not have significant recurrenc...Read more on AuntMinnie.comRelated Reading:
Ultrafast MRI shows promise in predicting DCIS upstaging
Ultrasound guidance effective in DCIS surgery
Researchers use microscopy technique to map breast tumor cells
AI helps identify breast lesion subtypes
Breast cancer overdiagnosis rates are low in mammography screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 16, 2022 Category: Radiology Source Type: news
Ultrasound guidance effective in DCIS surgery
Ultrasound-guided surgery in women with ductal carcinoma in situ (DCIS) is effectiv...Read more on AuntMinnie.comRelated Reading:
Breast ultrasound valuable in low-income countries
AI predicts breast cancer risk from normal ultrasound images
Lymphadenopathy on breast ultrasound lasts longer than reported
Artificial intelligence for breast ultrasound
Ultrasound jostles for bigger role in screening dense breasts (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 17, 2022 Category: Radiology Source Type: news
No Benefit From Endocrine Therapy After Mastectomy for DCIS No Benefit From Endocrine Therapy After Mastectomy for DCIS
Chinese investigators recommend ending the practice in patients with hormone-positive ductal carcinoma in situ. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
The Race to Make a Vaccine for Breast Cancer
When Karen Lynch was diagnosed with breast cancer at age 44, it was a shock, but not a complete surprise. “My family history is just riddled with cancer; my father had prostate cancer and died from stomach and esophageal cancer, and his five sisters passed from breast cancer,” she says. “My mother died from pancreatic cancer.” It was 1996, and genetic testing was not as routine as it is now, so it wasn’t until nine years after her diagnosis and treatment with lumpectomy and radiation that Lynch learned she carried the BRCA1 mutation, which increases her risk of breast cancer and ovarian cancer...
Source: TIME: Health - October 6, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer feature Frontiers of Medicine 2022 healthscienceclimate sponsorshipblock Source Type: news
Uninformed Breast Cancer Patients Are Making Treatment Decisions Uninformed Breast Cancer Patients Are Making Treatment Decisions
Women with ductal carcinoma in situ (DCIS) are generally uninformed about their diagnosis and are making uninformed treatment decisions, concludes a Dutch study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
